IPO registrations (S-1, F-1) · Registrants
ENvue Medical, Inc.
- SEC CIK
- 1326706 · filings on EDGAR ↗
- Name on the registration
- NanoVibronix, Inc.
- Former names
- NanoVibronix, Inc. (2014–2025); Nano Vibronix, Inc. (2011–2014); Nano Vibronix Inc (2005–2005)
- Registration
- Form S-1, first filed 2014-02-06, last 2025-05-14; 4 initial registrations, 20 amendments
- Outcome
- Final prospectus filed 2017-11-03; declared effective 2017-11-01; withdrawal requested 2015-02-09
- Industry (SIC)
- Orthopedic, Prosthetic & Surgical Appliances & Supplies 3842
- Incorporated in
- DE
- Business address
- 969 PRUITT AVE,, Tyler, TX 77569
- Ticker
- FEED (OTC)
- EDGAR entity type
- operating
- Insiders and CEO pay
- ENvue Medical, Inc. on the corporate pages
Offering terms
- Final price
- $4.90 per share (424B4 filed 2017-11-03)
- Shares sold
- 1,224,488
- Gross proceeds
- $5,999,991 before underwriting discounts and any over-allotment option
- Listing
- OTCQB under the symbol NAOV
- Lead underwriters
- Dawson James (1,020,407 shares)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form D issuer: NanoVibronix, Inc. EXACT (CIK (EXACT))
- SEC filer: ENvue Medical, Inc. EXACT (CIK (EXACT))
- Person page: Christopher M Fashek Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
Filings 41
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2014-02-06 | S-1 | S-1 (registration) | Nano Vibronix, Inc. | 0001144204-14-006520 ↗ |
| 2014-03-06 | S-1/A | S-1/A (amendment) | Nano Vibronix, Inc. | 0001144204-14-013884 ↗ |
| 2014-03-25 | S-1/A | S-1/A (amendment) | Nano Vibronix, Inc. | 0001144204-14-017621 ↗ |
| 2014-04-30 | S-1/A | S-1/A (amendment) | NanoVibronix, Inc. | 0001144204-14-026177 ↗ |
| 2014-05-02 | S-1/A | S-1/A (amendment) | NanoVibronix, Inc. | 0001144204-14-027100 ↗ |
| 2014-05-07 | S-1/A | S-1/A (amendment) | NanoVibronix, Inc. | 0001144204-14-028253 ↗ |
| 2014-05-08 | S-1/A | S-1/A (amendment) | NanoVibronix, Inc. | 0001144204-14-028721 ↗ |
| 2014-05-12 | S-1/A | S-1/A (amendment) | NanoVibronix, Inc. | 0001144204-14-029648 ↗ |
| 2014-06-23 | S-1/A | S-1/A (amendment) | NanoVibronix, Inc. | 0001144204-14-039017 ↗ |
| 2014-07-01 | S-1/A | S-1/A (amendment) | NanoVibronix, Inc. | 0001144204-14-040700 ↗ |
| 2014-07-07 | S-1/A | S-1/A (amendment) | NanoVibronix, Inc. | 0001144204-14-041656 ↗ |
| 2014-07-21 | S-1/A | S-1/A (amendment) | NanoVibronix, Inc. | 0001144204-14-043944 ↗ |
| 2015-02-09 | RW | RW (withdrawal request) | NanoVibronix, Inc. | 0001144204-15-007029 ↗ |
| 2015-02-12 | RW | RW (withdrawal request) | NanoVibronix, Inc. | 0001144204-15-008253 ↗ |
| 2017-06-21 | S-1 | S-1 (registration) | NanoVibronix, Inc. | 0001615774-17-003280 ↗ |
| 2017-06-26 | S-1/A | S-1/A (amendment) | NanoVibronix, Inc. | 0001615774-17-003374 ↗ |
| 2017-09-13 | S-1/A | S-1/A (amendment) | NanoVibronix, Inc. | 0001615774-17-005065 ↗ |
| 2017-10-18 | S-1/A | S-1/A (amendment) | NanoVibronix, Inc. | 0001615774-17-005758 ↗ |
| 2017-10-31 | S-1/A | S-1/A (amendment) | NanoVibronix, Inc. | 0001615774-17-006088 ↗ |
| 2017-11-01 | EFFECT | EFFECT (declared effective) | NanoVibronix, Inc. | 9999999995-17-002835 ↗ |
| 2017-11-03 | 424B4 | 424B4 (final prospectus) | NanoVibronix, Inc. | 0001615774-17-006191 ↗ |
| 2017-11-06 | 424B4 | 424B4 (final prospectus) | NanoVibronix, Inc. | 0001615774-17-006237 ↗ |
| 2019-05-23 | EFFECT | EFFECT (declared effective) | NanoVibronix, Inc. | 9999999995-19-001193 ↗ |
| 2020-01-29 | EFFECT | EFFECT (declared effective) | NanoVibronix, Inc. | 9999999995-20-000188 ↗ |
| 2020-08-11 | EFFECT | EFFECT (declared effective) | NanoVibronix, Inc. | 9999999995-20-002099 ↗ |
| 2020-12-15 | EFFECT | EFFECT (declared effective) | NanoVibronix, Inc. | 9999999995-20-003538 ↗ |
| 2023-07-17 | S-1 | S-1 (registration) | NanoVibronix, Inc. | 0001493152-23-024743 ↗ |
| 2023-08-07 | S-1/A | S-1/A (amendment) | NanoVibronix, Inc. | 0001493152-23-027051 ↗ |
| 2023-08-11 | EFFECT | EFFECT (declared effective) | NanoVibronix, Inc. | 9999999995-23-002359 ↗ |
| 2023-09-21 | RW | RW (withdrawal request) | NanoVibronix, Inc. | 0001493152-23-033294 ↗ |
| 2023-09-21 | EFFECT | EFFECT (declared effective) | NanoVibronix, Inc. | 9999999995-23-002717 ↗ |
| 2025-02-14 | S-1 | S-1 (registration) | NanoVibronix, Inc. | 0001493152-25-006878 ↗ |
| 2025-04-22 | S-1/A | S-1/A (amendment) | NanoVibronix, Inc. | 0001641172-25-005733 ↗ |
| 2025-04-29 | S-1/A | S-1/A (amendment) | NanoVibronix, Inc. | 0001641172-25-006708 ↗ |
| 2025-05-12 | S-1/A | S-1/A (amendment) | NanoVibronix, Inc. | 0001641172-25-009631 ↗ |
| 2025-05-14 | S-1/A | S-1/A (amendment) | NanoVibronix, Inc. | 0001641172-25-010173 ↗ |
| 2025-05-14 | EFFECT | EFFECT (declared effective) | NanoVibronix, Inc. | 9999999995-25-001590 ↗ |
| 2025-05-16 | 424B4 | 424B4 (final prospectus) | NanoVibronix, Inc. | 0001641172-25-011182 ↗ |
| 2025-12-18 | EFFECT | EFFECT (declared effective) | ENvue Medical, Inc. | 9999999995-25-003831 ↗ |
| 2026-05-28 | EFFECT | EFFECT (declared effective) | ENvue Medical, Inc. | 9999999995-26-001794 ↗ |
| 2026-09-03 | EFFECT | EFFECT (declared effective) | ENvue Medical, Inc. | 9999999995-26-002879 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2017-10-31 | S-1/A | registration statement | 857,143 | - | OTCQB NAOV | 2 | primary document; shares headline, cover names 2 | document ↗ | ||
| 2017-11-03 | 424B4 | final prospectus | $4.90 | 1,224,488 | $5,999,991 | OTCQB NAOV | 1 | primary document; price sentence, shares headline, proceeds computed, underwriting table 1, cover names 1 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| BROWN STEPHEN RUSSELL | Officer | Chief Financial Officer; SVP, Finance | 9 | 2015–2025 | |
| Goldstein Martin M | Director | 12 | 2015–2025 | ||
| GREENSTEIN IRA A | Director | 2 | 2015–2016 | ||
| JACOB HAROLD | Director,Officer | Chief Medical Officer | 5 | 2015–2025 | |
| Stern William | Director,Officer | Chief Executive Officer; President | 2 | 2015–2016 | |
| Zumeris Jona | Director,Officer | VP of Technology | 1 | 2015 | |
| Kelly Miriam W | TenPercentOwner | 1 | 2015 | ||
| Ferguson Michael | Director | 13 | 2015–2025 | ||
| MIKA THOMAS | Director | 14 | 2015–2025 | ||
| FASHEK CHRISTOPHER M | Director | 13 | 2016–2025 | person page Fuzzy | |
| Murphy Brian M | Director,Officer | Chief Executive Officer | 9 | 2016–2025 | |
| Cassirer Aurora | Director | 5 | 2022–2025 | ||
| Schroeder Maria | Director | 4 | 2022–2025 | ||
| Johnson David Ian | Director | 1 | 2025 | ||
| Pionati Pellegrino | Director | 1 | 2025 | ||
| Burgett Alison | Director | 1 | 2025 | ||
| Rotstein Zeev Jhoshua | Director | 1 | 2026 | ||
| BANK OF AMERICA CORP /DE/ | TenPercentOwner | 3 | 2026 | ||
| BANK OF AMERICA NA | TenPercentOwner | 3 | 2026 | ||
| BOFA SECURITIES, INC. | TenPercentOwner | 3 | 2026 | ||
| Glibert Christian Michael | Other; TenPercentOwner | 4 | 2026 | ||
| Fernandez-McGovern Nicole M. | Officer | Interim CFO | 1 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2023-09-13 | NanoVibronix, Inc. | Biotechnology | $13,546,513 | $13,546,513 | 1 | 1 |
| 2022-06-29 | NanoVibronix, Inc. | Biotechnology | $250,000 | $250,000 | 1 | 1 |
| 2021-02-05 | NanoVibronix, Inc. | Biotechnology | $1,254,206 | $1,254,206 | 3 | 1 |
| 2020-12-11 | NanoVibronix, Inc. | Biotechnology | $6,562,500 | $6,562,500 | 13 | 1 |
| 2020-08-18 | NanoVibronix, Inc. | Biotechnology | $0 | $0 | 1 | 1 |
| 2020-07-06 | NanoVibronix, Inc. | Biotechnology | $450,000 | $450,000 | 1 | 1 |
| 2017-04-03 | NanoVibronix, Inc. | Biotechnology | $250,000 | $250,000 | 3 | 1 |
| 2017-04-03 | NanoVibronix, Inc. | Biotechnology | $500,000 | $100,000 | 1 | 1 |
| 2015-05-01 | NanoVibronix, Inc. | Biotechnology | Indefinite | $257,000 | 1 | 1 |
| 2015-03-16 | NanoVibronix, Inc. | Biotechnology | Indefinite | $2,500,023 | 15 | 1 |
| 2015-03-16 | NanoVibronix, Inc. | Biotechnology | Indefinite | $218,269 | 11 | 1 |
| 2015-03-16 | NanoVibronix, Inc. | Biotechnology | Indefinite | $908,653 | 27 | 1 |
| 2015-03-16 | NanoVibronix, Inc. | Biotechnology | Indefinite | $3,150,000 | 7 | 1 |
| 2015-03-16 | NanoVibronix, Inc. | Biotechnology | Indefinite | $1,355,279 | 28 | 1 |
| 2015-03-16 | NanoVibronix, Inc. | Biotechnology | Indefinite | $1,500,000 | 2 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Form D issuer | NanoVibronix, Inc. | Form D private offerings | CIK (EXACT) | |
| Person page | Christopher M Fashek | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) | |
| SEC filer | ENvue Medical, Inc. | SEC filers (EDGAR) | CIK (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.